https://www.ilcn.org/supported_content/mariposa-os-data-confirms-improved-efficacy-for-amivantamab-plus-lazertinib-in-the-first-line-for-egfr-mutated-nsclc/ 2025-08-01T01:32:34+00:00 https://www.ilcn.org/wp-content/uploads/2025/04/25-ILCN-CI-Raez-Sandy-Combo-Feat.jpg https://www.ilcn.org/wp-content/uploads/2025/04/QA-v2.png https://www.ilcn.org/wp-content/uploads/2025/04/25-ILCN-Raez-Luis-4x6-1.jpg https://www.ilcn.org/wp-content/uploads/2025/04/25-ILCN-CI-Infographic-PatientPercentage-0414.jpg https://www.ilcn.org/wp-content/uploads/2025/04/25-ILCN-Sandy-Beth-4x6-1.jpg https://www.ilcn.org/wp-content/uploads/2025/04/25-ILCN-CI-Infographic-MedianSurvival-2.jpg https://www.ilcn.org/supported_content/cocoons-prophylactic-regimen-resulted-in-decreased-incidence-and-severity-of-dermatologic-related-adverse-events/ 2025-09-17T19:15:14+00:00 https://www.ilcn.org/wp-content/uploads/2025/05/25-ILCN-CI-Dietrich-Singer-Combo-Feat.jpg https://www.ilcn.org/wp-content/uploads/2025/04/QA-v2.png https://www.ilcn.org/wp-content/uploads/2025/05/25-ILCN-Dietrich_Martin-4x6.v1.jpg https://www.ilcn.org/wp-content/uploads/2025/05/ILCNinfographs-Rybrevant-LR1.jpg https://www.ilcn.org/wp-content/uploads/2025/05/25-ILCN-Singer_Alyson-4x6.v1.jpg https://www.ilcn.org/wp-content/uploads/2025/05/25-ILCN-c0156132-v2.jpg https://www.ilcn.org/wp-content/uploads/2025/05/25-ILCN-c0156132-v2.jpg